Acrivon Therapeutics, Inc. · NASDAQ:ACRV

Acrivon Therapeutics, Inc. financial statements

Acrivon Therapeutics, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue000000
Cost of revenue1.36M1.01M536.0K1.09M832.0K13.0K
Gross profit-1.36M-1.01M-536.0K-1.09M-832.0K-13.0K
Research and development60.0M64.0M46.0M23.9M13.7M1.87M
Selling, general and administrative24.1M25.2M21.1M8.71M2.47M1.30M
Operating income-84.1M-89.2M-67.1M-32.7M-16.2M-3.17M
Depreciation and amortization1.36M1.01M536.0K364.0K37.0K13.0K
EBITDA-82.8M-88.2M-66.6M-32.3M-16.1M-3.15M
Interest expense1.49M59.0K
Income before tax-77.8M-80.4M-60.4M-31.2M-16.2M-5.31M
Income tax01-1.49M-199.6K-193.3K
Net income-77.9M-80.6M-60.4M-31.2M-16.2M-5.31M
Earnings per share, basic-2.02-2.38-2.74-7.56-9.32-0.41
Earnings per share, diluted-2.02-2.38-2.74-7.56-9.32

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents41.5M39.8M36.0M29.5M99.6M1.58M
Short-term investments77.1M139.7M91.4M98.2M0
Current assets120.4M181.6M129.7M132.1M100.4M1.72M
Property, plant and equipment4.89M4.47M3.48M2.09M290.0K59.0K
Total assets129.7M196.6M138.3M181.2M106.6M2.19M
Accounts payable2.28M758.0K5.05M904.0K964.0K136.0K
Current liabilities15.7M17.2M13.3M6.52M2.91M613.0K
Total debt2.71M3.65M4.64M4.96M5.63M58.0K
Total liabilities17.2M19.8M17.1M10.8M7.88M10.6M
Shareholders' equity112.5M176.8M121.2M170.5M-23.8M-8.41M
Shares outstanding31.6M31.2M22.5M21.9M1.77M12.9M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-63.7M-65.7M-42.6M-30.1M-14.0M-2.80M
Capital spending-1.67M-2.77M-1.29M-2.17M-238.0K-15.0K
Free cash flow-65.3M-68.4M-43.9M-32.3M-14.2M-2.82M
Cash from investing66.1M-51.8M50.7M-141.7M-238.0K-15.0K
Cash from financing-749.0K121.0M-1.55M101.7M112.2M2.89M
Share buybacks101.7M
Change in cash1.69M3.59M6.52M-70.1M98.0M71.0K